New combo injection targets Hard-to-Treat head and neck tumors

NCT ID NCT07625423

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new approach for people with head and neck cancer that has returned or spread after standard chemotherapy. The treatment combines a gene therapy injection (EDS01) given directly into a tumor with an immunotherapy drug (toripalimab) given through a vein. The study will enroll 9 adults to check safety and see if the tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: recombinant human endostatin adenovirus (EDS01) and toripalimab
What this could lead to: If it works, this could point toward a new treatment option for people with head and neck cancer that has come back or spread.
What could go wrong: This is a very early, small Phase 1 trial with only 9 participants, so it is mainly checking safety. The combination may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer head and neck neoplasm Head and Neck Neoplasms nasopharyngeal carcinoma nasopharyngeal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD NECK CANCER NASOPHARYNGEAL CANCINOMA (NPC)

Contacts and locations

Locations

West China Hospital
RECRUITING

Chengdu, China, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.